A large randomized trial suggests that newer blood thinners can significantly reduce serious cardiovascular events in people with atrial fibrillation who face an intermediate risk of stroke. The findings from the SINGLE-AF trial, presented during a Hot Line session at ESC Congress 2026 and published concurrently in the New England Journal of Medicine, offer compelling evidence for a shift in treatment paradigms for a significant patient population where anticoagulant therapy has historically been a subject of debate. The study demonstrated that treatment with oral anticoagulants was associated with a substantial reduction in adverse clinical events compared with no anticoagulant therapy.
The Ambiguous Landscape of Atrial Fibrillation Treatment for Intermediate-Risk Patients
Atrial fibrillation (AF), a common cardiac arrhythmia characterized by an irregular and often rapid heart rate, poses a significant public health challenge. It affects millions worldwide and is a leading cause of preventable stroke. The irregular electrical activity in the atria can lead to blood pooling and clot formation, which can then travel to the brain, causing an ischemic stroke.
Current international guidelines, such as those from the European Society of Cardiology (ESC), strongly advocate for the use of oral anticoagulants (OACs) in patients with AF who are classified as high risk for stroke. This risk is typically assessed using validated scoring systems like CHA2DS2-VASc, which considers factors such as congestive heart failure, hypertension, age, diabetes, previous stroke or transient ischemic attack (TIA), vascular disease, and sex. However, for individuals categorized as having an intermediate risk of stroke, the recommendation has remained less definitive, with anticoagulant treatment being considered rather than mandated.
This "gray area" in clinical practice has persisted for years, largely due to inconsistencies observed in earlier research. While observational studies have explored the efficacy and safety of anticoagulants in this group, particularly the older vitamin K antagonist (VKA) drugs like warfarin, their results have often been mixed and subject to confounding factors. These drugs, while effective, require careful monitoring of blood clotting levels (INR) and are associated with a higher risk of bleeding complications if not managed precisely. The absence of robust, large-scale randomized controlled trials (RCTs) specifically addressing the benefit of newer anticoagulants in intermediate-risk AF patients has contributed to this uncertainty.
Professor Boyoung Joung, the Principal Investigator of the SINGLE-AF trial and a distinguished figure from Yonsei University in Seoul, South Korea, articulated the rationale behind the study: "Evidence from observational studies with anticoagulants, particularly vitamin K antagonists, remains conflicting in those at intermediate risk. SINGLE-AF was conducted to provide the first evidence from a randomized trial on whether newer direct oral anticoagulants (DOACs) are beneficial in patients with AF at intermediate risk of stroke." This statement highlights the critical need for high-quality evidence to guide clinical decision-making for a substantial segment of the AF population.
SINGLE-AF: A Rigorous Examination of Newer Anticoagulants
The SINGLE-AF trial was meticulously designed as an open-label, randomized controlled study, a gold standard for establishing causal relationships in clinical research. The trial was conducted across 18 prominent medical centers in South Korea, a region known for its advanced healthcare infrastructure and strong research capabilities. The study enrolled a total of 1,803 participants diagnosed with atrial fibrillation. A key inclusion criterion was that these individuals were considered to be at an intermediate risk of stroke, precisely defined by a CHA2DS2-VASc score of 1 in men or 2 in women. This stratification is crucial as it targets a population that has historically fallen into a therapeutic uncertainty.
Participants were prospectively randomized in a 1:1 ratio, ensuring that each group had an equal chance of receiving either treatment or the control. One arm of the study involved treatment with newer direct oral anticoagulants (DOACs). Specifically, participants received either apixaban 5 mg administered twice daily or rivaroxaban 20 mg taken once daily. These DOACs represent a significant advancement over VKAs, offering predictable pharmacokinetics, fixed dosing, and a generally lower risk of major bleeding, thereby simplifying management and potentially improving patient adherence. The comparator arm of the trial involved participants receiving no anticoagulant therapy, serving as a crucial baseline to quantify the absolute benefit of the DOACs.
The trial’s design, particularly its randomized nature and the use of modern anticoagulants, aimed to overcome the limitations of previous observational data and provide definitive evidence for this specific patient subgroup. The open-label nature, while a potential source of bias, was deemed acceptable in this context given the clear distinction in treatment (active medication versus no medication) and the robust primary endpoint, which included objective clinical events.
Landmark Findings: A Dramatic Reduction in Serious Cardiovascular Events
The results of the SINGLE-AF trial, after a median follow-up period of 24 months, delivered a powerful message regarding the efficacy of DOACs in intermediate-risk AF patients. The researchers reported a remarkable 69% reduction in the trial’s primary composite endpoint among patients receiving DOACs compared to those in the control group who received no anticoagulation. This primary endpoint was meticulously designed to capture a comprehensive picture of serious adverse outcomes and included a composite of stroke, systemic embolism (blood clots traveling to other parts of the body), major bleeding, and cardiovascular death.
Delving deeper into the data, serious events occurred in a significantly lower proportion of patients in the DOAC group: only 0.5% of participants experienced such events. In stark contrast, the group receiving no anticoagulant therapy saw a 1.5% incidence of these serious adverse events. This difference was statistically significant (p=0.028) and yielded a hazard ratio of 0.31 (95% confidence interval 0.10 to 0.94), strongly indicating that DOAC therapy was associated with a substantial protective effect.
Further analysis revealed that the significant reduction in the primary endpoint was largely driven by a dramatic decrease in the incidence of ischemic strokes. Ischemic strokes, caused by a blockage of blood flow to the brain, are a major cause of disability and mortality. In the SINGLE-AF trial, ischemic strokes occurred in a mere 0.1% of patients taking DOACs, a stark contrast to the 1.1% observed in the group receiving no anticoagulation. This finding alone underscores the immense value of timely and appropriate anticoagulant therapy in preventing devastating neurological events.
Crucially, the trial also addressed a primary concern with anticoagulant therapy: the risk of bleeding. A major safety endpoint of the study was the incidence of major bleeding, defined according to established criteria. In a testament to the safety profile of modern DOACs, the SINGLE-AF trial did not find an increase in major bleeding events in the treatment arm. Major bleeding occurred in 0.3% of patients receiving DOAC therapy, which was comparable to the 0.5% observed in the group that did not receive anticoagulation. This finding is of paramount importance, as it demonstrates that the significant reduction in thrombotic events was achieved without a commensurate increase in potentially life-threatening bleeding complications, a common trade-off that has complicated treatment decisions in the past.
Implications for Clinical Practice and Future Guidelines
The findings from the SINGLE-AF trial are poised to have a profound impact on the management of atrial fibrillation, particularly for the substantial population of patients who fall into the intermediate-risk category. For years, clinicians have navigated a complex landscape where the benefits of anticoagulation were well-established for high-risk patients but less certain for those with intermediate risk. This new, robust evidence from a randomized trial provides a clear, evidence-based rationale for initiating DOAC therapy in this previously ambiguous group.
Professor Joung’s concluding remarks eloquently summarize the significance of these findings: "We now have evidence from a randomized trial that patients with AF at intermediate stroke risk benefit from DOAC therapy, without an increase in major bleeding. Data from the SINGLE-AF trial may be used to inform future guideline recommendations and reimbursement policies." This statement points towards a potential paradigm shift in clinical practice guidelines. It suggests that the current recommendation for "considering" anticoagulation for intermediate-risk patients may evolve to a stronger recommendation for initiation of therapy, especially with DOACs.
The implications extend beyond clinical guidelines. Reimbursement policies by healthcare providers and insurers often align with established guidelines. The clear demonstration of efficacy and safety in SINGLE-AF could lead to improved access to DOACs for intermediate-risk AF patients, reducing the financial barriers that may have previously limited their use. This could translate into millions of patients worldwide receiving potentially life-saving treatment.
Furthermore, the study provides valuable insights into the comparative effectiveness of newer anticoagulants versus no treatment in a population that has historically been undertreated or treated with less optimal agents. The reduction in composite endpoints, driven primarily by a significant decrease in ischemic strokes without an increase in major bleeding, highlights the favorable risk-benefit profile of DOACs in this context.
Broader Context and Future Directions
The SINGLE-AF trial adds to a growing body of evidence supporting the use of DOACs across various AF patient populations. Earlier trials such as RE-LY (for dabigatran), ROCKET AF (for rivaroxaban), and AVERROES and ARISTOTLE (for apixaban) had already established the non-inferiority or superiority of DOACs compared to warfarin in high-risk AF patients. However, the intermediate-risk group remained a key area where more definitive data was needed.
The success of SINGLE-AF in demonstrating a clear benefit in this specific group is particularly noteworthy. It suggests that the prophylactic effect of anticoagulation against thromboembolic events is significant even at lower baseline risk levels, provided appropriate agents are used. This also raises questions about the optimal duration of anticoagulation and whether certain subgroups within the intermediate-risk category might derive even greater benefit.
Future research may focus on refining risk stratification within the intermediate-risk category, exploring personalized treatment approaches, and continuing to monitor long-term outcomes and safety profiles of DOACs. The trial’s success in South Korea also opens avenues for similar large-scale trials in diverse ethnic and geographical populations to ensure generalizability of findings.
In conclusion, the SINGLE-AF trial represents a pivotal moment in the management of atrial fibrillation. By providing robust randomized evidence, it effectively bridges the therapeutic gap for intermediate-risk patients, offering them a significant reduction in serious cardiovascular events with an acceptable safety profile. This landmark study is expected to influence clinical practice, update international guidelines, and ultimately improve the lives of countless individuals living with atrial fibrillation worldwide. The clarity it brings to a long-standing area of clinical uncertainty is a testament to the power of rigorous scientific investigation.
